MoonLake Immunotherapeutics (NASDAQ:MLTX), Inc. is a clinical-stage biopharmaceutical company focused on harnessing the body’s innate immune response to treat cancer and other serious diseases. The company’s core research centers on modulating the Stimulator of Interferon Genes (STING) pathway, a critical component of the immune system that can trigger robust anti-tumor activity. By developing novel STING agonists and complementary oligonucleotide therapies, MoonLake aims to improve patient outcomes in solid tumors and explore new applications in inflammatory and metabolic disorders.
The company’s lead asset, MTL-001, is a proprietary cyclic dinucleotide designed for optimized activation of STING in the tumor microenvironment. Preclinical studies have demonstrated that local administration of MTL-001 can recruit and activate antigen-presenting cells, boosting both innate and adaptive immune responses against malignant cells. In parallel, MoonLake is advancing MTL-CEBPA, an RNA oligonucleotide that restores the expression of the transcription factor CEBPA in suppressive myeloid cells, thereby reprogramming the immune landscape and enhancing the efficacy of checkpoint inhibitors.
Founded in 2018 as a spin-out from leading academic laboratories in Europe and the United States, MoonLake has built a diverse pipeline of immunotherapies supported by collaborations with major research institutions. The company operates research and development sites in San Diego, California, and Paris, France, allowing it to leverage scientific talent on both sides of the Atlantic. Strategic partnerships with clinical centers and pharmaceutical firms have enabled MoonLake to accelerate its translational programs and prepare for mid-stage clinical trials.
MoonLake’s executive leadership team combines expertise in oncology drug development, translational immunology and regulatory strategy. Guided by a seasoned board of directors with backgrounds in biotechnology investment and corporate governance, the company is committed to advancing its pipeline through clinical proof-of-concept and beyond. With a growing network of academic and industry collaborators, MoonLake Immunotherapeutics seeks to establish new standards of care in cancer immunotherapy and related fields.
